Is this similar to what peregrine has or diffrent? Can someone please let me know the difference thanks PORTLAND, Ore. & CAMBRIDGE, Mass. & DETROIT–(BUSINESS WIRE)–#drugdiscovery–Asterand Bioscience, the leader in high quality, well-characterized
human tissue and human tissue-based research solutions supporting drug
discovery and development, announced today a partnership with
MolecularMD to combine MolecularMD’s expertise as a provider of
molecular diagnostics products and services with Asterand Bio’s drug
target and candidate validation capabilities. MolecularMD is a molecular
diagnostics company that develops custom clinical trial assays as well
as companion diagnostic products, supporting clinical trial services and
commercialization of targeted cancer therapies. The partnership creates
an end-to-end workflow for biopharma clients and strengthens the
companies’ current offerings in assay development & validation, while
creating a global footprint for the efficient delivery of clinical trial
sample analyses.
“For over 20 years, Asterand Bioscience’s experienced scientists have
worked collaboratively with clients to expedite the highest likelihood
for clinical success by providing a variety of pre-clinical
research services,” said John Canepa, Chief Financial Officer/Chief
Operations Officer. “This agreement brings together MolecularMD’s proven
track record in clinical assay development and companion diagnostics
with Asterand Bio’s human tissue procurement, characterization and
research services to provide a comprehensive approach to meet the needs
of pharmaceutical, biotechnology and diagnostic companies from
validation of biomarkers and targets to assay development, through
regulatory and clinical trials.”
“MolecularMD is uniquely suited to assist biopharma clients with our
clinical trial and regulatory expertise,” said Dan Snyder,
President/Chief Executive Officer, MolecularMD. “I’m excited that
Asterand Bio and MolecularMD have joined forces to provide these unique
advantages which will help our broad client base accelerate their
pipeline decisions and dramatically improve the efficiency of the
clinical trial and commercialization workflow.”
Asterand Bio and MolecularMD will both attend Molecular Med Tri-Con
2017, Feb 19-24 at the Moscone North Convention Center, San Francisco,
CA, a meeting bringing together over 3,500 drug discovery and
development professionals. More information about the partnership can be
found at Asterand Bio’s booth #626. Asterand Bio and MolecularMD will
both attend the AACR 2017 meeting, April 1-5 at the Walter E. Washington
Convention Center in Washington DC, a meeting that highlights the
highest level of cancer science and medicine from institutions all over
the world. More information about the partnership can be found at
Asterand Bio’s booth #1340 and MolecularMD’s booth #3423.
About Asterand Bioscience
Asterand Bioscience is the leading global provider of high quality,
well-characterized human tissue and human tissue-based research
solutions to drug discovery scientists. Our mission is to provide
human-based solutions to accelerate the identification and validation of
drug targets and enhance the selection of drug candidates with increased
likelihood of clinical success. From our offices in Detroit, MI and
Royston, U.K. our employees are focused on providing services and
products to accelerate drug discovery research from target
identification through to compound evaluation and drug safety.
About MolecularMD
MolecularMD Corporation develops and commercializes specialty molecular
diagnostics for oncology applications. Tests are designed to allow
appropriate selection, monitoring and management of patients treated
with molecularly-targeted cancer therapies. MolecularMD integrates
gold-standard and innovative platform technologies with clinical assay
design, validation and centralized testing to accelerate all phases of
clinical development, including FDA approval and commercialization of in
vitro companion diagnostic tests for novel anticancer agents.
Contacts
AI
